Tag: GlobeNewswire

The following is an update to the third quarter 2026 outlook and gives an overview of our current expectations for the third quarter. Outlooks presented may vary from the actual third quarter 2026 results and are subject to finalisation of those results, which are scheduled to be published on 29 October, 2026. Unless otherwise indicated, all outlook statements exclude identified items. 

See appendix for the definition of the non-GAAP measure used, the reconciliation from GAAP to non-GAAP and the most comparable GAAP measure.

   Integrated Gas

$ billions	Q2’26	Q3’26 Outlook	Comment
Production (kboe/d)	631	740 – 780
LNG liquefaction volumes (MT)	7.7	7.2 – 7.6
Underlying opex	1.1	1.3 – 1.5
Pre-tax depreciation	1.2	1.1 – 1.5
Taxation charge	0.8	0.6 – 0.9
Other Considerations:
Trading & Optimisation is expected to be in line with Q2’26. Outlook includes the acquisition of ARC resources, which completed on 2 September, 2026.

 Upstream

$ billions	Q2’26	Q3’26 Outlook	Comment
Production (kboe/d)	1,824	1,735 – 1,835
Underlying opex	2.2	2.1 – 2.5
Pre-tax depreciation	2.5	2.2 – 2.8
Taxation charge	2.8	2.5 – 3.3
Other Considerations:
Q3’26 exploration well write-offs are expected to be ~$0.3 billion.

 Marketing

$ billions	Q2’26	Q3’26 Outlook	Comment
Sales volumes (kb/d)	2,570	2,550 – 2,650
Underlying opex	2.5	2.3 – 2.7
Pre-tax depreciation	0.6	0.5 – 0.7
Taxation charge	0.4	0.2 – 0.5
Other Considerations:
Marketing adjusted earnings are expected to be lower than Q2’26.

  Chemicals and Products

$ billions	Q2’26	Q3’26 Outlook	Comment
Indicative refining margin*	$24/bbl	$42/bbl
Indicative chemicals margin*	$270/tonne	$208/tonne
Refinery utilisation	102%	93% – 97%	Low Rhine water levels impacting Rheinland refinery utilisation.
Chemicals utilisation	83%	81% – 85%
Underlying opex	1.9	1.7 – 2.1
Pre-tax depreciation	1.1	1.1 – 1.3
Taxation charge / (credit)	0.6	1.0 – 1.5
Other Considerations:
Trading & Optimisation is expected to be in line with Q2’26.

*See appendix

 Renewables and Energy Solutions

$ billions	Q2’26	Q3’26 Outlook	Comment
Adjusted Earnings	0.1	0.0 – 0.4

  

Corporate

$ billions	Q2’26	Q3’26 Outlook	Comment
Adjusted Earnings	(0.6)	(0.8) – (0.6)

Shell Group

$ billions	Q2’26	Q3’26 Outlook	Comment
CFFO:
Tax paid	2.9	3.1 – 3.9
Financial Derivative Instruments movements	(0.4)	0 – 5
Other	0.1	(4) – 1	CFFO excluding working capital is expected to include an ~$2.5 billion outflow related to timing of payments of emissions certificates relating to the German BEHG*.
Working capital	3.4	(4) – 1
Other Shell Group Considerations:
CFFO excluding working capital includes a $0.8 billion JV dividend inflow, which is offset by a $0.8 billion outflow through working capital (as funds were previously held in deposit by the corporate segment). The net impact on CFFO is zero.
Non-cash post tax impairments of biogas assets in Marketing are expected to be largely offset by an impairment reversal in Integrated Gas. Both are reported as identified items.
Net debt will be impacted by ARC acquisition cash consideration & assumption of debt and an increase in variable components of long-term shipping leases in the current macro environment.

*Brennstoffemissionshandelsgesetz (Fuel Emissions Trading Act), historically paid in the 4th quarter of each calender year

Guidance

The ‘Quarterly Databook’ contains guidance on Indicative Refining Margin, Indicative Chemicals Margin and full-year price and margin sensitivities.

Consensus

The company compiled consensus, managed by Vara Research, is expected to be published on October 21, 2026.

Appendix

Indicative Margins

Chemicals & Products	Q2’26	Q3’26 Updated Outlook
Indicative refining margin	$24/bbl	$42/bbl
Indicative chemicals margin	$270/tonne	$208/tonne

Volume Data

Operational Metrics	Q2’26	Q3’26 QPR Outlook	Q3’26 Updated Outlook
Integrated Gas
Production (kboe/d)	631	570 – 630*	740 – 780
LNG liquefaction volumes (MT)	7.7	7.1 – 7.7	7.2 – 7.6
Upstream
Production (kboe/d)	1,824	1,680 – 1,880	1,735 – 1,835
Marketing
Sales volumes (kb/d)	2,570	2,550 – 2,750	2,550 – 2,650
Chemicals & Products
Refinery utilisation	102%	93% – 101%	93% – 97%
Chemicals utilisation	83%	78% – 86%	81% – 85%

*Q3’26 QPR production outlook excluded volumes from ARC Resources and Qatar.

Underlying Opex

Underlying operating expenses is a measure aimed at facilitating a comparative understanding of performance from period to period by removing the effects of identified items, which, either individually or collectively, can cause volatility, in some cases driven by external factors. Underlying operating expenses comprises the following items from the Consolidated statement of Income: production and manufacturing expenses; selling, distribution and administrative expenses; and research and development expenses and removes the effects of identified items such as redundancy and restructuring charges or reversals, provisions or reversals and others. For further details see the 2nd Quarter 2026 and half year unaudited results.

$ billions	Q2’26	Q2’26 Adjusted	Q3’26 Updated Outlook
Production and manufacturing expenses	5.5
Selling, distribution and administrative expenses	2.9
Research and development	0.3
Operating Expenses (Opex)	8.7	8.7
Less: Identified Items		0.2
Underlying Opex		8.4
of which:
Integrated Gas	1.1	1.1	1.3 – 1.5
Upstream	2.2	2.2	2.1 – 2.5
Marketing	2.5	2.5	2.3 – 2.7
Chemicals and Products	2.0	1.9	1.7 – 2.1
Renewables and Energy Solutions	0.6	0.6

Depreciation, depletion and amortisation

$ billions	Q2’26	Q2’26 Adjusted	Q3’26 Updated Outlook
Depreciation, Depletion & Amortisation	6.2	6.2
Less: Identified Items		0.6
Pre-tax depreciation (as Adjusted)		5.6
of which:
Integrated Gas	1.2	1.2	1.1 – 1.5
Upstream	2.5	2.5	2.2 – 2.8
Marketing	0.6	0.6	0.5 – 0.7
Chemicals and Products	1.2	1.1	1.1 – 1.3
Renewables and Energy Solutions	0.7	0.1

Taxation Charge

$ billions	Q2’26	Q2’26 Adjusted	Q3’26 Updated Outlook
Taxation Charge	4.9	4.9
Less: Identified Items and Cost of supplies adjustment		0.4
Taxation Charge (as Adjusted)		4.5
of which:
Integrated Gas	0.8	0.8	0.6 – 0.9
Upstream	2.7	2.8	2.5 – 3.3
Marketing	0.7	0.4	0.2 – 0.5
Chemicals and Products	1.0	0.6	1.0 – 1.5
Renewables and Energy Solutions	(0.1)	—

Adjusted Earnings

The “Adjusted Earnings” measure aims to facilitate a comparative understanding of Shell’s financial performance from period to period by removing the effects of oil price changes on inventory carrying amounts and removing the effects of identified items. These items are in some cases driven by external factors and may, either individually or collectively, hinder the comparative understanding of Shell’s financial results from period to period. This measure excludes earnings attributable to non-controlling interest. For further details see the 2nd Quarter 2026 and half year unaudited results.

$ billions	Q2’26	Q2’26 Adjusted	Q3’26 Updated Outlook
Income/(loss) attributable to Shell plc shareholders	10.8	10.8
Add: Current cost of supplies adjustment attributable to Shell plc shareholders		(0.6)
Less: Identified items attributable to Shell plc shareholders		0.4
Adjusted Earnings		9.8
of which:
Renewables and Energy Solutions	(0.6)	0.1	0.0 – 0.4
Corporate	(0.6)	(0.6)	(0.8) – (0.6)

Working Capital

Working capital movements are defined as the sum of the following items in the Consolidated Statement of Cash Flows: (i) (increase)/decrease in inventories, (ii) (increase)/decrease in current receivables, and (iii) increase/(decrease) in current payables.

Net Debt

Net debt is defined as the sum of current and non-current debt, less cash and cash equivalents, adjusted for the fair value of derivative financial instruments used to hedge foreign exchange and interest rate risks relating to debt, and associated collateral balances.

Enquiries

Media International: +44 (0) 207 934 5550

Media U.S. and Canada: Contact form

Cautionary Note

The companies in which Shell plc directly and indirectly owns investments are separate legal entities. In this announcement “Shell”, “Shell Group” and “Group” are sometimes used for convenience to reference Shell plc and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Shell plc and its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. ‘‘Subsidiaries’’, “Shell subsidiaries” and “Shell companies” as used in this announcement refer to entities over which Shell plc either directly or indirectly has control. The terms “joint venture”, “joint operations”, “joint arrangements”, and “associates” may also be used to refer to a commercial arrangement in which Shell has a direct or indirect ownership interest with one or more parties.  The term “Shell interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Shell in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.

The numbers presented in this announcement may not sum precisely to the totals provided and percentages may not precisely reflect the absolute figures due to rounding.

Forward-Looking statements
This announcement contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition, results of operations and businesses of Shell. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions, including (without limitation) those concerning Shell’s strategy and operating plans, macroeconomic conditions, future energy demand, supply and product mix, commodity prices, demand for Shell’s products, production results and reserve estimates, development, execution and management of projects, energy transition and climate change, management of safety and environmental risks, costs, cash capital expenditures, technology advancements, legislative, judicial, fiscal and regulatory developments, regional conflicts and trading conditions, and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Shell to market risks and statements expressing management’s expectations, beliefs, estimates, forecasts, projections and assumptions. These forward-looking statements are identified by their use of terms and phrases such as “aim”; “ambition”; ‘‘anticipate’’; “aspire”; “aspiration”; ‘‘believe’’; “commit”; “commitment”; ‘‘could’’; “desire”; ‘‘estimate’’; ‘‘expect’’; ‘‘goals’’; ‘‘intend’’; ‘‘may’’; “milestones”; ‘‘objectives’’; ‘‘outlook’’; ‘‘plan’’; ‘‘probably’’; ‘‘project’’; ‘‘risks’’; “schedule”; ‘‘seek’’; ‘‘should’’; ‘‘target’’; “vision”; ‘‘will’’; “would” and similar terms and phrases. There are a number of factors that could affect the future operations of Shell and could cause those results to differ materially from those expressed in the forward-looking statements included in this announcement, including (without limitation): (a) price fluctuations in crude oil and natural gas; (b) changes in demand for Shell’s products; (c) currency fluctuations; (d) drilling and production results; (e) reserves estimates; (f) loss of market share and industry competition; (g) environmental and physical risks, including climate change; (h) risks associated with the identification of suitable potential acquisition properties and targets, and successful negotiation and completion of such transactions; (i) the risk of doing business in developing countries and countries subject to international sanctions; (j) legislative, judicial, fiscal and regulatory developments including tariffs and regulatory measures addressing climate change; (k) economic and financial market conditions in various countries and regions; (l) political risks, including the risks of expropriation and renegotiation of the terms of contracts with governmental entities, delays or advancements in the approval of projects and delays in the reimbursement for shared costs; (m) risks associated with the impact of pandemics, regional conflicts, such as the Russia-Ukraine war and the conflict in the Middle East, and a significant cyber security, data privacy or IT incident; (n) the pace of the energy transition; and (o) changes in trading conditions. No assurance is provided that future dividend payments will match or exceed previous dividend payments. All forward-looking statements contained in this announcement are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Additional risk factors that may affect future results are contained in Shell plc’s Form 20-F for the year ended December 31, 2025 (available at www.shell.com/investors/news-and-filings/sec-filings.html and www.sec.gov). These risk factors also expressly qualify all forward-looking statements contained in this announcement and should be considered by the reader. Each forward-looking statement speaks only as of the date of this announcement, October 7, 2026. Neither Shell plc nor any of its subsidiaries undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this announcement.

Shell’s net carbon intensity and net-zero emissions target
In this announcement we may refer to Shell’s “net carbon intensity” (NCI), which includes Shell’s carbon emissions from the production of our energy products, our suppliers’ carbon emissions in supplying energy for that production and our customers’ carbon emissions associated with their use of the energy products we sell. Shell’s NCI also includes the emissions associated with the production and use of energy products produced by others which Shell purchases for resale. Shell only controls its own emissions. The use of the terms Shell’s “net carbon intensity” or NCI is for convenience only and not intended to suggest these emissions are those of Shell plc or its subsidiaries.

Shell’s operating plan and outlook are forecasted for a three-year period and ten-year period, respectively, and are updated every year. They reflect the current economic environment and what we can reasonably expect to see over the next three and ten years. Accordingly, the outlook reflects our combined Scope 1 and 2 target, NCI targets and our oil products ambition over the next ten years. However, Shell’s operating plan and outlook cannot reflect our 2050 net-zero emissions target, as this target is outside our planning period. Such future operating plans and outlooks could include changes to our portfolio, efficiency improvements and the use of carbon capture and storage and carbon credits. In the future, as society moves towards net-zero emissions, we expect Shell’s operating plans and outlooks to reflect this movement. However, if society is not net zero in 2050, as of today, there would be significant risk that Shell may not meet this target.

The information provided above regarding Shell’s NCI and net zero emissions target are not intended, nor should they be construed as introducing, suggesting or making any claim, target or representation thereof other than what is included in the announcement.

Forward-Looking Non-GAAP measures

This announcement may contain certain forward-looking non-GAAP measures such as Adjusted Earnings, Cash flow from operating activities excluding working capital movements, Net debt and Underlying operating expense.

We are unable to provide a reconciliation of these forward-looking non-GAAP measures to the most comparable GAAP financial measures because certain information needed to reconcile those non-GAAP measures to the most comparable GAAP financial measures is dependent on future events some of which are outside the control of Shell, such as oil and gas prices, interest rates and exchange rates. Moreover, estimating such GAAP measures with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without unreasonable effort. Non-GAAP measures in respect of future periods which cannot be reconciled to the most comparable GAAP financial measure are calculated in a manner which is consistent with the accounting policies applied in Shell plc’s consolidated financial statements. These forward-looking non-GAAP measures are provided to assist readers in understanding management’s use and expectations of such measures and may not be appropriate for other purposes. 

The contents of websites referred to in this announcement do not form part of this announcement.

We may have used certain terms, such as resources, in this announcement that the United States Securities and Exchange Commission (SEC) strictly prohibits us from including in our filings with the SEC. Investors are urged to consider closely the disclosure in our Form 20-F, File No 1-32575, available on the SEC website www.sec.gov.

7 October 2026

Transaction in own shares

Admiral Group plc (the “Company”) announces that for the period 30 September 2026 to 6 October 2026 it has purchased for cancellation 250,000 of its ordinary shares of 0.1 pence each (‘ordinary shares’), as detailed below, through the Company’s broker UBS AG, London Branch (“UBS“) as part of its buy-back announced on 30 September 2026.

Date of Purchase	Aggregate number of ordinary shares purchased	Volume weighted average price (GB pence)	Highest Price per share (GB pence)	Lowest Price per share (GB pence)	Trading venue
30 September 2026	22,000	3,647.5156	3,686.00	3,620.00	London Stock Exchange
30 September 2026	19,000	3,642.0444	3,684.00	3,620.00	BATS Europe
30 September 2026	6,000	3,642.8340	3,680.00	3,622.00	Chi-X Europe
30 September 2026	3,000	3,643.1220	3,674.00	3,622.00	Aquis
01 October 2026	22,126	3580.7399	3596.00	3554.00	London Stock Exchange
01 October 2026	18,874	3579.9839	3596.00	3558.00	BATS Europe
01 October 2026	6,000	3580.2047	3592.00	3564.00	Chi-X Europe
01 October 2026	3,000	3580.6727	3592.00	3564.00	Aquis
02 October 2026	22,737	3,600.4567	3,632.00	3,580.00	London Stock Exchange
02 October 2026	18,442	3,598.0853	3,632.00	3,574.00	BATS Europe
02 October 2026	5,821	3,597.7007	3,624.00	3,578.00	Chi-X Europe
02 October 2026	3,000	3,597.3713	3,624.00	3,576.00	Aquis
05 October 2026	22,125	3601.6494	3622.00	3576.00	London Stock Exchange
05 October 2026	18,913	3602.7581	3622.00	3576.00	BATS Europe
05 October 2026	5,667	3602.9642	3626.00	3580.00	Chi-X Europe
05 October 2026	3,295	3602.7781	3616.00	3574.00	Aquis
06 October 2026	22,084	3616.5730	3658.00	3590.00	London Stock Exchange
06 October 2026	19,013	3616.5150	3656.00	3592.00	BATS Europe
06 October 2026	5,617	3616.6028	3656.00	3588.00	Chi-X Europe
06 October 2026	3,286	3615.6762	3654.00	3594.00	Aquis

The Company intends to cancel all of the purchased ordinary shares.

Following the cancellation of the repurchased shares reported above, the Company’s issued share capital will consist of 306,054,676 ordinary shares with voting rights.

There are no ordinary shares held in Treasury.

The above figure (306,054,676) may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company’s under the FCA’s Disclosure Guidance and Transparency Rules.

From the commencement of the share buy-back programme on 30 September 2026, the Company has purchased 250,000 ordinary shares in aggregate at a weighted average price of 3,608.57p per ordinary share.

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended, a full breakdown of the individual purchases of ordinary shares made by UBS on behalf of the Company can be found in the link to this announcement.

Schedule of purchases – 30.06.26 – 06.10.26

– ENDS –

For further information, please contact:

Media:        
Sian Broad                                sian.broad5@admiralgroup.co.uk         

Investors/ Analysts:        
Jelena Bjelanovic                        investorrelationssupport@admiralgroup.co.uk

Attachment

• Schedule of purchases – 30.06.26 – 06.10.26

SINGAPORE, Oct. 07, 2026 (GLOBE NEWSWIRE) — Valeura Energy Inc. (TSX:VLE, OTCQX:VLERF) (“Valeura” or the “Company”) provides an operations and financial update for Q3 2026.

Highlights

• Oil production averaged 22.1 mbbls/d⁽¹⁾;
• Sales of 2.013 million bbls;
• Price realisations averaged US$97.4/bbl, resulting in revenue of US$196.1 million;
• Cash position of US$384.9 million at 30 September 2026⁽²⁾ and no debt;
• Exploration discovery on Block G1/48⁽³⁾ – the Suraphi oil field;
• Final investment decision on the first phase of development of the Bussabong gas field, on Block G3/65⁽⁴⁾;
• Milestone cumulative production of 100 million bbls of oil from the Jasmine field as of 21 September 2026⁽⁵⁾; and
• Early completion of onshore construction of the Wassana central processing platform (“CPP”), on track for accelerated installation in the field in Block G10/48⁽⁶⁾, starting in October 2026.

^{(1) Working interest share production, before royalties.
(2) Includes restricted cash of US$15.8 million.
(3) Block G1/48, 90% operated working interest.
(4) Block G3/65, 40% non-operated working interest; Thailand’s cabinet has granted executive approval for the assignment of interest to Valeura. Completion anticipated in October 2026.
(5) Block B5/27, 100% operated interest.
(6) Block G10/48, 100% operated interest.}

Dr. Sean Guest, President and CEO commented:
“Our Q3 2026 production was exactly on plan, and once again, confirms our guidance expectations for the full year 2026. Operational performance has been very strong, with no deviations from our high standards on health, safety, and environmental stewardship. At the same time, our financial performance has been remarkable as the Company is able to capture full benefit of current oil prices as it carries no hedging, operates under simple tax/royalty-based fiscal terms, and benefits from historic tax loss carry-forwards. Our balance sheet is stronger than ever before, with US$385 million in cash and no debt.

During Q3, we advanced several strategic priorities including securing government approval for our Block G1/65 and G3/65 farm-in⁽¹⁾, and thereafter taking a final investment decision to pursue the first phase of gas development on the Bussabong field. We are also encouraged by the potential for additional oil development on Block G1/48 as a result of our exploration discovery of the Suraphi field, which we believe has the potential to extend the productive life of the Manora field and may support further exploration and development opportunities in the area.

We also achieved a key milestone at our Jasmine field this quarter, with cumulative production hitting the milestone of 100 million barrels of oil produced to date. More recently, our Wassana redevelopment project achieved a key milestone as well. Onshore construction of our new-build CPP was completed early and is on track for accelerated installation, starting in October 2026.

Operationally and financially, our business is delivering extremely well and I am pleased to see external recognition of this across all aspects of our business. This quarter we were recognised by the Toronto Stock Exchange as one of the top 30 performing companies based on three-year share price performance. We received four awards from the Thailand Ministry of Environment for our environmental monitoring practices. And finally, our Company’s approach to adopting new technology was recognised by the Society of Petroleum Engineers in Thailand in response to our introduction of complex multi-lateral drilling at the Nong Yao field. ”

^{(1) 40% non-operated working interest.}

Q3 2026 Update
Valeura’s working interest share production before royalties was on plan for Q3 2026, averaging 22.1 mbbls/d. The Company sold a total of 2.013 million bbls of oil during the quarter with average realised prices of US$97.4/bbl, resulting in revenue of US$196.1 million. Revenue includes crude oil receivables of US$22.5 million at 30 September 2026, in respect of oil sales just prior to the end of the quarter. The Company anticipates collecting upon such receivable in the early part of Q4 2026.

The Company’s cash position increased to US$384.9 million at 30 September 2026. Valeura has no debt.

Wassana CPP Completion
Onshore construction of the Wassana CPP was fully completed on 01 October 2026. Jacket and CPP have been loaded on to vessels for transportation and installation on the field, starting in October. This follows the installation of an oil export pipeline which will connect the new CPP to the floating storage and offloading vessel, which was completed in September, on plan and budget.    The Company is planning to begin development drilling late in 2026.  

Overall, the Company’s plan to accelerate the original Wassana redevelopment project schedule by approximately two months is on track. Management continues to forecast first oil production from the CPP at approximately the beginning of Q2 2027.

Results Timing
Valeura intends to release its full unaudited financial and operating results for Q3 2026 on 11 November 2026 and will discuss the results in more detail through a management webcast.

For further information, please contact:

Valeura Energy Inc. (General Corporate Enquiries)                +65 6373 6940
Sean Guest, President and CEO
Yacine Ben-Meriem, CFO
Contact@valeuraenergy.com  

Valeura Energy Inc. (Investor and Media Enquiries)                +1 403 975 6752
Robin James Martin, SVP, Communications and Investor Relations
IR@valeuraenergy.com

Contact details for the Company’s advisors, covering research analysts and joint brokers, including ATB Cormark Capital Markets, Auctus Advisors LLP, Beacon Securities Limited, Canaccord Genuity Ltd (UK), Research Capital Corporation, Roth Canada Inc., and Stifel Nicolaus Europe Limited, are listed on the Company’s website at www.valeuraenergy.com/investor-information/analysts/.

About the Company

Valeura Energy Inc. is a Canadian public company engaged in the exploration, development and production of petroleum and natural gas in Thailand and Türkiye. The Company is executing a growth-oriented strategy, reinvesting into its producing asset portfolio while deploying capital toward further organic and inorganic growth across Southeast Asia. Valeura is committed to delivering value-accretive growth for all stakeholders, underpinned by high standards of environmental, social and governance responsibility.

Additional information relating to Valeura is also available on SEDAR+ at www.sedarplus.ca.

Unaudited Financial Information

Certain anticipated financial and operating results for Q3 2026 in this news release are preliminary estimates based on unaudited financial information. These preliminary figures have not been audited or reviewed by the Company’s auditor and remain subject to change, which changes could be material, upon completion of the Company’s unaudited interim financial statements for the three and nine months ended 30 September 2026 and management’s final review.

Advisory and Caution Regarding Forward-Looking Information

Certain information included in this news release constitutes forward-looking information under applicable securities legislation. Such forward-looking information is for the purpose of explaining management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes, such as making investment decisions. Forward-looking information typically contains statements with words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “estimate”, “propose”, “project”, “target” or similar words suggesting future outcomes or statements regarding an outlook. Forward-looking information in this news release includes, but is not limited to: the potential for more oil development on Block G1/48 as a result of the Company’s exploration discovery of the Suraphi field; and timing for the installation of the Wassana CPP, development drilling, and first oil production.    Forward-looking information is based on management’s current expectations and assumptions regarding, among other things: political stability of the areas in which the Company is operating and the continuity of existing fiscal and regulatory regimes; continued safety of operations and ability to proceed in a timely manner; continued operations of and approvals forthcoming from governments and regulators in a manner consistent with past conduct, including approval of gas pricing and formalization of gas sales agreements; future drilling activity on the required/expected timelines; the prospectivity of the Company’s lands; the continued favourable pricing and operating netbacks across its business; future production rates and associated operating netbacks and cash flow; decline rates; future sources of funding; future economic conditions; the impact of inflation on future costs; future currency exchange rates; interest rates; the ability to meet drilling deadlines and fulfil commitments under licences and leases; future commodity prices; the impact of geopolitical conflicts, including conflicts in the Middle East, and between Russia and Ukraine; royalty rates and taxes; future capital and other expenditures; the success obtained in drilling new wells and working over existing wellbores; the performance of wells and facilities; the availability of the required capital to fund its exploration, development and other operations, and the ability of the Company to meet its commitments and financial obligations; the ability of the Company to secure adequate processing, transportation, fractionation and storage capacity on acceptable terms, including access to processing facilities; the capacity and reliability of facilities; the application of regulatory requirements respecting abandonment and reclamation; the recoverability of the Company’s reserves and contingent resources; future growth; the sufficiency of budgeted capital expenditures in carrying out planned activities; the impact of increasing competition; the ability to efficiently integrate assets and employees acquired through acquisitions; global energy policies going forward; future debt levels; the Company’s continued ability to obtain and retain qualified staff and equipment in a timely and cost efficient manner; PTTEP’s continued participation as operator and joint venture partner in accordance with expectations; the timely completion of construction and deployment of wellhead platforms; and the continued applicability of customary Thai domestic gas pricing frameworks. In addition, the Company’s work programmes and budgets are in part based upon expected agreement among joint venture partners and associated exploration, development and marketing plans and anticipated costs and sales prices, which are subject to change based on, among other things, the actual results of drilling and related activity, availability of drilling, offshore storage and offloading facilities and other specialised oilfield equipment and service providers, changes in partners’ plans and unexpected delays and changes in market conditions. Although the Company believes the expectations and assumptions reflected in such forward-looking information are reasonable, they may prove to be incorrect.

Forward-looking information involves significant known and unknown risks and uncertainties. Exploration, appraisal, and development of oil and natural gas reserves and resources are speculative activities and involve a degree of risk. A number of factors could cause actual results to differ materially from those anticipated by the Company including, but not limited to: the ability of management to execute its business plan or realise anticipated benefits from the Farm-in and the Bussabong development, including the risk that actual capital expenditures exceed estimates or that development timelines are delayed; the risk of disruptions from public health emergencies and/or pandemics; competition for specialised equipment and human resources; the Company’s ability to manage growth; the Company’s ability to manage the costs related to inflation; disruption in supply chains; the risk of currency fluctuations; changes in interest rates, oil and gas prices and netbacks; potential changes in joint venture partner strategies and participation in work programmes; uncertainty regarding the contemplated timelines and costs for work programme execution; the risks of disruption to operations and access to worksites; potential changes in laws and regulations, the uncertainty regarding government and other approvals; counterparty risk; the risk that financing may not be available; risks associated with weather delays and natural disasters; geopolitical risks and instability; and the risk associated with international activity. See the Company’s most recent annual information form and the MD&A for a detailed discussion of the risk factors.

The forward-looking information contained in this news release is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless required by applicable securities laws. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, including where such offer would be unlawful. This news release is not for distribution or release, directly or indirectly, in or into the United States, Ireland, the Republic of South Africa or Japan or any other jurisdiction in which its publication or distribution would be unlawful.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this news release.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) — VAALCO Energy, Inc. (NYSE: EGY, LSE: EGY) (“Vaalco” or the “Company”) announced successful completion of the offshore Gabon Phase 3 drilling program, including encouraging initial well results on the ETSEM-3H well and demobilization of the rig from the SE Etame platform. Additionally, the Company provided updates on the recently commenced Baobab drilling program offshore Côte d’Ivoire.

Operational Highlights:

• Offshore Gabon, successfully drilled, completed and placed on production the ETSEM-3H development well in an attic position within the SE Etame field, with a lateral wellbore of 300 meters of net pay in high-quality Gamba reservoir sands;
  • Achieved stabilized initial flow rate of approximately 2,000 gross barrels of oil per day (“BOPD”), 1,140 BOPD net to Vaalco;
  • Phase 3 drilling program is now complete; and
  • Drill rig (Borr Norve) has been demobilized from the field.

• Offshore Côte d’Ivoire, the Baobab Phase 5 drilling operations have begun with the batch-setting of top-holes by the operator;
  • After the top-hole sections of all wells are drilled, the wells will then be completed and placed on production sequentially; and
  • First producer well anticipated online near end of 2026 supporting meaningful expected production growth in 2027.

George Maxwell, Vaalco’s Chief Executive Officer, commented, “We are pleased with the results of the ETSEM-3H development well, which was landed in an attic location within the SE Etame field, and is now on production at about 2,000 gross BOPD (1,140 BOPD net to Vaalco). This represents the final well in our successful Phase 3 drilling campaign, and the drilling rig has now been demobilized from the field. In Côte d’Ivoire, following the successful re-start of the Baobab field during the second quarter, we have now commenced the Phase 5 drilling campaign with batch-setting the top-hole sections of the new wells. The current plan for the Phase 5 drilling campaign consists of four producers, three water injectors and two workovers. We expect to have the first new producer online near the end of the year, with meaningful production increases expected in 2027. Our continued success and organic project pipeline support Vaalco’s strategic focus on growing production, reserves and value for our shareholders.”

About Vaalco

Vaalco Energy Inc. is an African-focused independent energy company with a diversified portfolio of production, development and exploration assets in Gabon, Egypt, Côte d’Ivoire and Equatorial Guinea. The Company combines cash-generative production assets with development and exploration opportunities supported by existing infrastructure and established operating histories. 

Since 2021, Vaalco has transformed from a single-asset producer into a multi-country African operator through disciplined acquisitions, portfolio optimization and operational delivery. Led by an experienced management team with a proven track record of value creation, Vaalco combines disciplined capital allocation, shareholder returns and a visible, self-funded pathway to significantly increase production from resources already within its portfolio.

Vaalco is headquartered in Houston and listed on the New York Stock Exchange and the Main Market of the London Stock Exchange under the symbol EGY. For further information, visit www.vaalco.com.

Vaalco’s Legal Entity Identifier (LEI) is 549300CFHFVIWB8M6T24.

For Further Information

Vaalco Energy, Inc. (General and Investor Enquiries)	+00 1 713 543 3422
Website:	www.vaalco.com
Al Petrie Advisors (US Investor Relations)	+00 1 713 543 3422
Al Petrie / Chris Delange
Camarco (Financial PR)
Georgia Edmonds / Rebecca Waterworth (UK)	+44 20 3757 4980
Rosie Driscoll (US)	+00 1 771 241 3164

Forward Looking Statements

Information in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Where a forward-looking statement expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. All statements other than statements of historical fact may be forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “forecast,” “outlook,” “aim,” “target,” “will,” “could,” “should,” “may,” “likely,” “plan” and “probably” or similar words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, but are not limited to, statements relating to (i) estimates of future drilling, production, sales and costs of acquiring crude oil, natural gas and natural gas liquids; (ii) expectations regarding future exploration and the development, growth and potential of Vaalco’s operations, project pipeline and investments, and schedule and anticipated benefits to be derived therefrom; (iii) expectations regarding future acquisitions, investments or divestitures; (iv) expectations of future dividends; (v) expectations of future balance sheet strength; and (vi) expectations of future equity and enterprise value.

Such forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to: risks relating to any unforeseen liabilities of Vaalco; the ability to generate cash flows that, along with cash on hand, will be sufficient to support operations and cash requirements; risks related to early production data not being indicative of long-term performance; and the risks described under the caption “Risk Factors” in Vaalco’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC.

Any forward-looking statement made by Vaalco in this press release, is based only on information currently available to Vaalco and speaks only as of the date on which it is made. Except as may be required by applicable securities laws, Vaalco undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Inside Information

This announcement contains inside information as defined in Regulation (EU) No. 596/2014 on market abuse which is part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (“MAR”) and is made in accordance with the Company’s obligations under article 17 of MAR. The person responsible for arranging the release of this announcement on behalf of Vaalco is Matthew Powers, Corporate Secretary of Vaalco.

Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end

ZUG, Switzerland, October 7, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that Riad Sherif, M.D., Chief Executive Officer of Oculis, will present at Eyecelerator @ AAO 2026 on October 8, 2026, and that the Company will sponsor the Neuro-Ophthalmology Subspecialty Day at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting on October 9, 2026, in New Orleans, Louisiana. 

At Eyecelerator @ AAO 2026, Dr. Sherif will present Licaminlimab, a novel topical anti-TNFα candidate being developed with a genotype-based precision medicine approach for TNFR1-mediated dry eye disease, in the PREDICT-1 registrational symptoms trial on track for topline readout around year-end.

Oculis will also partner with the Neuro-Ophthalmology Subspecialty Day, reflecting the Company’s commitment to advancing neuro-ophthalmology through scientific exchange, education, and collaboration with experts in research, clinical practice, and emerging technologies to improve care for patients with neuro-ophthalmic diseases. 

Riad Sherif, M.D., Chief Executive Officer of Oculis, said: “AAO provides a valuable opportunity to engage with the broader ophthalmology and neuro-ophthalmology communities and discuss how innovation can address persistent unmet needs in both fields. The upcoming topline results from PREDICT-1 have the potential to further advance our aim of bringing precision medicine to TNFR1-mediated dry eye disease, while the continued progress of Privosegtor reflects our commitment to transforming outcomes for patients facing neuro-ophthalmic diseases. Together, these programs illustrate Oculis’ strategy of pursuing highly differentiated therapies with the potential to redefine standards of care.”

Details of Oculis’ presentation at Eyecelerator @ AAO 2026 are as follows: 

Session: Anterior segment showcase
Date / Time: October 8, 1:24 PM CDT
Room: 243-245
Presenter: Riad Sherif, M.D., Chief Executive Officer

– Ends –

About Licaminlimab 

Licaminlimab is an anti-TNFα eye drop candidate being developed with a single chain antibody fragment (scFv) technology specifically developed to treat ocular inflammatory diseases. The dual anti-inflammatory and anti-necrotic mechanism of action of TNFα inhibition is well established in inflammatory disorders, where systemic use of TNFα inhibitors has led to marked improvements in disease management and treatment outcomes. In Phase 2 trials, Licaminlimab has shown a positive treatment effect on both the signs and symptoms of dry eye disease and has been well tolerated. In addition, a genetic biomarker has been identified that showed a more pronounced treatment effect with Licaminlimab in patients with a specific TNFR1 genotype. If approved, Licaminlimab has the potential to transform the treatment paradigm with a precision medicine approach. 

Licaminlimab is an investigational drug in a registrational trial and has not received regulatory approval for commercial use in any country. 

About Privosegtor 

Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improvements in visual function, corroborated by anatomical preservation of the retina, including GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis and multiple sclerosis, where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility in the multiple sclerosis model. 

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Priority Medicines (PRIME) designation from the European Medicines Agency, as well as Orphan Drug designation from both agencies for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy. 

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country. 

About Oculis 

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis and non-arteritic anterior ischemic optic neuropathy. Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial and is being developed with a genotype-based approach for treating patients with dry eye disease. Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. 

For more information, please visit: www.oculis.com 

Contacts 

Oculis Contact 
Ms. Sylvia Cheung, CFO 
sylvia.cheung@oculis.com 

Investor Relations 
LifeSci Advisors 
Corey Davis, Ph.D. 
cdavis@lifesciadvisors.com 

Media Relations 
ICR Healthcare 
Amber Fennell / David Daley / Sean Leous 
oculis@icrhealthcare.com 

Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotective therapy for optic neuritis and other neuro-ophthalmic and neuro-axonal diseases and the potential for Licaminlimab to transform the treatment paradigm in dry eye disease with a precision medicine approach; the initiation, enrollment, timing, progress and results of current and future clinical trials; Oculis’ research and development programs, regulatory and business strategy; Oculis’ future development plans; the timing or likelihood of regulatory filings and approvals; and statements about market opportunity, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and subject to risks, variability and contingencies, many of which are beyond Oculis’ control. Results from prior clinical trials may not be replicated in later clinical trials. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those expected and/or expressed or implied by such forward-looking statements, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. 

Elis announces the results of the conversion and exchange period
for its 2029 OCEANEs

Puteaux, October 7, 2026 – Elis (the “Company”) announces the results of the conversion/exchange period for its €380,000,000 2.25% bonds convertible into new shares and/or exchangeable for existing shares due September 22, 2029 (ISIN FR001400AFJ9) (the “Bonds”).

On September 11, 2026, the Company announced its decision to redeem all outstanding Bonds on October 13, 2026, pursuant to the first paragraph of Condition 1.10.1.3, “Early redemption at the Company’s option”, of the terms and conditions of the Bonds dated September 22, 2022 (the “Terms and Conditions”).

Capitalised terms that are not otherwise defined in this notice shall have the meanings given to them in the Terms and Conditions.

Bondholders had until October 2, 2026, to validly exercise their Conversion/Exchange Rights in accordance with the Terms and Conditions, at a conversion/exchange ratio of 6,256.8564 Elis shares per Bond.

A total of 3,767 Bonds were validly presented for conversion/exchange, representing 99.13% of the 3,800 Bonds outstanding on September 11, 2026. With a par value of €100,000 per Bond, this represents an aggregate nominal amount of €376,700,000.

Applying the Conversion/Exchange Ratio and the rounding provisions of the Terms and Conditions, these exercises will result in the delivery of a total of 23,569,556 Elis shares (ISIN FR0012435121), comprising 18,104,556 existing shares held in treasury and 5,465,000 new shares, representing in aggregate 9.89% of Elis’s share capital following the issuance of the new shares. The share capital of the Company now amounts to EUR 238,313,588, comprising 238,313,588 ordinary shares with a nominal value of EUR 1.00 each. The Company will use existing shares held following the completion of its share buyback program on July 9, 2026, thereby limiting the number of new shares to be issued. Settlement and delivery of the shares will be completed on October 7, 2026.

The remaining 33 Bonds, in respect of which conversion/exchange rights were not validly exercised, will be redeemed in cash on October 13, 2026, at a price of €100,129.45 per Bond, including €129.45 of accrued interest, representing an aggregate redemption amount of €3,304,271.85.

IMPORTANT NOTICE

This press release does not constitute an offer to sell, a solicitation of an offer to purchase, or an offer to purchase any securities of Elis in any jurisdiction.

Contacts

Nicolas Buron
Director of Investor Relations, Financing & Treasury
Phone: + 33 (0)1 75 49 98 30 – nicolas.buron@elis.com

Charline Lefaucheux
Investor Relations
Phone: + 33 (0)1 75 49 98 15 – charline.lefaucheux@elis.com

Attachment

• Elis announces the results of the conversion and exchange period for its 2029 OCEANEs

First patient enrolled in cohort combining bexobrutideg with venetoclax

Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL

Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies

BRISBANE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the Phase 1b/2 NX-5948-203 study evaluating bexobrutideg, an investigational oral Bruton’s tyrosine kinase (BTK) degrader, in combination with venetoclax, a standard-of-care therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

The study is being conducted under the global collaboration between Nurix and Roche and is designed to evaluate the safety, tolerability and clinical activity of bexobrutideg in combination with venetoclax, a BCL2 inhibitor. Data from the trial are expected to inform future registrational development strategies across lines of therapy in CLL, including evaluating bexobrutideg in combination with the anti-CD20 antibodies rituximab and obinutuzumab across multiple cohorts of patients with relapsed or refractory and previously untreated CLL, and potential expansion into other B-cell malignancies.

“The initiation of this study marks another important milestone in our effort to realize the full potential of bexobrutideg across B-cell malignancies,” said Arthur T. Sands, M.D., Ph.D., chief executive officer of Nurix. “Combination therapies are becoming increasingly important in the treatment of CLL, especially in earlier lines of therapy, and we believe bexobrutideg’s differentiated mechanism of action, robust single-agent activity and favorable tolerability make it an attractive partner for combination approaches to deliver deep, durable responses with fixed-duration therapy.”

About Bexobrutideg (NX-5948)
Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of Bruton’s tyrosine kinase (BTK) being developed by Nurix and Roche as a potential best-in-class therapy across oncology, immunology and neurology.

​​​Bexobrutideg is currently being evaluated in a broad clinical development program in patients with chronic lymphocytic leukemia (CLL), including the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study in patients with relapsed/refractory CLL previously treated with covalent and noncovalent BTKi and a BCL2i; the DAYBreak CLL-306 clinical trial (NCT07516093), a randomized Phase 3 trial comparing bexobrutideg to pirtobrutinib in patients with relapsed/refractory CLL previously treated with a covalent BTKi; the NX-5948-203 Phase 1b/2 clinical trial (NCT07520006), assessing the combination of bexobrutideg with venetoclax in patients with relapsed/refractory CLL and potentially treatment-naïve CLL; and the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) in patients with relapsed/refractory B-cell malignancies. Additional information about these clinical trials can be found at clinicaltrials.gov.

About Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical-stage oncology pipeline includes bexobrutideg, a degrader of BTK being co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix’s autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and clinical-stage degraders of IRAK4 in collaboration with Gilead and STAT6 in collaboration with Sanofi. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates in its wholly owned preclinical pipeline and under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information, visit www.nurixtx.com.

Forward-Looking Statements
This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding Nurix’s plans for the development of bexobrutideg and the potential of bexobrutideg to serve as a foundational component of future combination regimens. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) whether Nurix and Roche will be able to successfully conduct and complete clinical development of bexobrutideg pursuant to the Nurix-Roche collaboration; (ii) the unexpected emergence of adverse events or other undesirable side effects during clinical development; (iii) whether Nurix will have adequate resources to fund its obligations under the Nurix-Roche collaboration; (iv) whether the parties will be able to successfully co-commercialize bexobrutideg in the United States; and (v) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal period ended May 31, 2026, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Contacts:
Media & Investors
Kris Fortner
Nurix Therapeutics, Inc.
kfortner@nurixtx.com

SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The shares of common stock, pre-funded warrants and notes to be sold in the offerings are being offered by Vaxcyte. Vaxcyte has granted the underwriters of the common stock and pre-funded warrant offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price per share, and has granted the underwriters of the note offering a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes at the public offering price, solely to cover over-allotments, in each case less underwriting discounts and commissions.

The aggregate gross proceeds to Vaxcyte from the common stock and pre-funded warrants offering are expected to be approximately $500 million and the aggregate gross proceeds to Vaxcyte from the notes offering are expected to be $500 million, in each case before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters’ options.

Vaxcyte intends to use the net proceeds from the offerings to fund (i) clinical development of the VAX-31 adult and pediatric programs, including (a) for the ongoing VAX-31 adult Phase 3 program, the trial evaluating concomitant administration with a seasonal influenza vaccine (OPUS-2, enrolled), the trial in adults who have previously received a pneumococcal vaccine (OPUS-3, enrolled) and the planned manufacturing consistency study, and the anticipated topline safety, tolerability and immunogenicity data announcements from such studies, and (b) for the VAX-31 infant Phase 2 dose-finding study (enrolled), the anticipated topline data announcement(s) from the primary three-dose immunization series and booster dose; (ii) manufacturing scale-up, processes and supply to support our clinical studies and the potential commercial launches of our PCV programs, including (a) to establish additional manufacturing capacity to meet potential incremental supply requirements for the global adult and pediatric populations following the potential initial commercial launch of VAX-31 in adults in the United States and (b) to build inventory levels in advance of such potential commercial launch; (iii) medical affairs, commercial and systems-related investments to prepare for and execute the anticipated U.S. launch of VAX-31 in adults; (iv) ongoing research and development of our other early-stage pipeline vaccine candidates; and (v) general corporate purposes, including working capital, operating expenses and capital expenditures, as well as potential expansion of Vaxcyte’s research pipeline.

The completion of the common stock and pre-funded warrant offering is not contingent on the completion of the note offering, and the completion of the note offering is not contingent on the completion of the common stock and pre-funded warrant offering.

The offerings are expected to close on October 9, 2026, subject to the satisfaction of customary closing conditions.

Jefferies, Leerink Partners, BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC and Guggenheim Securities are acting as joint book-running managers for the common stock and pre-funded warrant offering. Mizuho is acting as bookrunner and BTIG is acting as lead manager for the common stock and pre-funded warrant offering.

Jefferies, Leerink Partners, BofA Securities, Goldman Sachs & Co. LLC and Evercore ISI are acting as joint book-running managers for the note offering. Guggenheim Securities and Mizuho are acting as bookrunners and Needham & Company is acting as lead manager for the note offering.

J. Wood Capital Advisors is acting as financial advisor to Vaxcyte in connection with the note offering.

The notes will be senior, unsecured obligations of Vaxcyte and will accrue interest at a rate of 1.50% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, beginning on April 15, 2027. The notes will mature on October 15, 2032, unless earlier repurchased, redeemed or converted. Before July 15, 2032, noteholders will have the right to convert their notes only upon the occurrence of certain events. From and after July 15, 2032, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Vaxcyte will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Vaxcyte’s election. The initial conversion rate is 11.1607 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $89.60 per share of common stock. The initial conversion price represents a premium of approximately 40.0% over the public offering price per share of common stock in the common stock offering. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Vaxcyte’s option at any time, and from time to time, on or after October 22, 2029 and on or before the 20th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Vaxcyte’s common stock exceeds 130% of the conversion price for a specified period of time. The notes will also be redeemable, in whole and not in part, for cash at Vaxcyte’s election at any time if the principal amount of the notes then outstanding is less than 10% of the aggregate principal amount of the notes issued in this offering (including any additional notes issued pursuant to any exercise of the underwriters’ option to purchase additional notes). The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

If a “fundamental change” (as defined in the indenture for the notes) occurs, then, subject to a limited exception, noteholders may require Vaxcyte to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.

A shelf registration statement relating to the offered securities was filed with the Securities and Exchange Commission (SEC) and was automatically effective upon filing on May 24, 2024. A preliminary prospectus supplement and accompanying prospectus relating to each offering has been filed, and a final prospectus supplement and accompanying prospectus relating to each offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to each offering may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by email at syndicate@leerink.com or by phone at (800) 808-7525, ext. 6105.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Vaxcyte

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, has generated positive Phase 2 clinical results in both adults and infants and is designed to cover more serotypes than any PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages Vaxcyte’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in Vaxcyte’s PCV franchise.

VAX-A1 is a prophylactic vaccine candidate designed to provide broad, strain-independent protection against disease caused by Group A Strep and is currently being evaluated in a Phase 1 clinical study in adults. Group A Strep remains a significant global cause of morbidity and mortality across both adult and pediatric populations and is a leading driver of antibiotic use, underscoring the substantial public health burden.

Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, Vaxcyte’s system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-GI, a vaccine candidate designed to prevent Shigella.

Forward-Looking Statements

This press release contains forward-looking statements regarding Vaxcyte, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the completion, timing and expected closing of the offerings, the expected amount of the gross proceeds of the offerings and the intended use of the net proceeds therefrom. Words such as “expects,” “intends,” “intended,” “designed,” “aim,” “will” and “may” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements represent Vaxcyte’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market and other conditions, the satisfaction of the closing conditions related to the offerings, risks described under the caption “Risk Factors” in the preliminary prospectus supplements (and, when available, the final prospectus supplements) for the offerings, risks relating to Vaxcyte’s business, and the other risks described more fully in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. Vaxcyte may not consummate the offerings described in this press release and, if the offerings are consummated, cannot provide any assurances regarding its ability to effectively apply the net proceeds as described above. You should not place undue reliance on these forward-looking statements. The forward-looking statements included in this press release speak only as of the date of this press release, and Vaxcyte does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law.

Contacts:

Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com

Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
investors@vaxcyte.com

Digital Realty’s Osaka campus expands with commencement of construction on a new 24 MW facility designed for high-density computing and advanced cooling

SINGAPORE, Oct. 07, 2026 (GLOBE NEWSWIRE) — Digital Realty (NYSE: DLR), the world’s largest cloud- and carrier-neutral data center platform, today announced the commencement of construction of KIX15, a new 24 megawatt (MW) data center at its KIX Campus in Ibaraki City, Osaka Prefecture, Japan.

Developed by MC Digital Realty (MCDR), Digital Realty’s 50/50 joint venture in Japan with Mitsubishi Corporation, KIX15 will be the fifth data center at the KIX Campus and is scheduled to commence operations in the fourth quarter of 2028. The new facility is planned to further expand Digital Realty’s presence across the Tokyo and Osaka metropolitan areas. Upon completion, KIX15 will bring MCDR’s Japan portfolio to 10 data centers, representing approximately 220 MW of aggregate IT capacity.

This expansion follows the opening of the NRT14 Data Center in Inzai City, Chiba Prefecture, earlier this year. NRT14 is one of the first facilities in Japan to achieve the DGX-Ready Data Center certification.

KIX15 will be part of PlatformDIGITAL^®, Digital Realty’s global data center platform spanning 300+ data centers across 55+ metros in 30+ countries on six continents.

Serene Nah, Managing Director and Head of Asia Pacific, Digital Realty, said, “Japan is a strategic market for Digital Realty and a key part of our long-term growth in Asia Pacific. Our continued investment in Japan reflects both our confidence in the market and our commitment to building the infrastructure customers will need for the long term.

“KIX15 is the next step in that commitment. As customer requirements become more distributed and complex, the combination of local scale and global reach will become increasingly important.”

Advancing AI Infrastructure in Kansai

KIX15 is a key component of MCDR’s Kansai AI Infrastructure Co-Creation Project, an initiative centered on the KIX Campus to support the development of AI infrastructure across the Kansai region.

The project brings together the expansion of the KIX Campus with stronger domestic and international connectivity and deeper collaboration with telecommunications and technology partners.

Kohei Yamashita, Representative Director and Chief Executive Officer of MC Digital Realty, said, “Kansai has a growing opportunity to play a larger role in Japan’s AI economy. Realizing that potential will require an ecosystem that can support businesses as they build and scale AI, bringing together computing infrastructure, connectivity and technology expertise.”

As adoption of generative AI and cloud services grows, demand is increasing for higher-density computing environments, advanced cooling and reliable connectivity in Japan. KIX15 is designed to support hybrid air- and liquid-cooling technologies. Designed to provide a high level of security and campus-based scalability, the facility is expected to support a broad range of customers, including hyperscalers, cloud service providers and companies deploying AI infrastructure.

Through Digital Realty’s ServiceFabric^® orchestration and interconnection platform and collaboration with multiple network service providers, customers will have access to low-latency connectivity to key locations and cloud services in Japan and more than 300 Digital Realty data centers worldwide. This enables customers to expand into high-power, high-density infrastructure at the KIX Campus while maintaining connectivity with their existing IT environments.

About Digital Realty
Digital Realty brings companies and data together by delivering the full spectrum of data center, colocation, and interconnection solutions. PlatformDIGITAL^®, the company’s global data center platform, provides customers with a secure data meeting place and a proven Pervasive Datacenter Architecture (PDx^®) solution methodology for powering innovation, from cloud and digital transformation to emerging technologies like artificial intelligence (AI), and efficiently managing Data Gravity challenges. Digital Realty gives its customers access to the connected data communities that matter to them with a global data center footprint of 300+ facilities in 55+ metros across 30+ countries on six continents. To learn more about Digital Realty, please visit digitalrealty.com or follow us on LinkedIn and X.

About MC Digital Realty
MC Digital Realty, Inc., established in September 2017, is a 50/50 joint venture between Mitsubishi Corporation and Digital Realty. The company provides the full spectrum of data center services in Japan, including colocation and interconnection solutions, by leveraging Mitsubishi Corporation’s real estate and infrastructure investment expertise and customer network, as well as Digital Realty’s global data center platform, PlatformDIGITAL^®.

For Additional Information

Media Contacts
Joyce Ng
Digital Realty
jong@digitalrealty.com

Investor Relations
Jordan Sadler / Jim Huseby
Digital Realty
+1 (737) 281-0101
InvestorRelations@digitalrealty.com

Safe Harbor Statement
This press release contains forward-looking statements which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially, including statements related to the Asian markets, the company’s development plans, expected completion dates, expected growth in digital transformation and demand, customer demand and the company’s strategy. For a list and description of risks and uncertainties, see the reports and other filings by the company with the U.S. Securities and Exchange Commission. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ab8f4779-e20a-4c84-8555-2c9d13184fbb

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) — Figure Technology Solutions, Inc. (Nasdaq: FIGR; OPEN: FGRS) (“Figure”), the leading blockchain-native capital marketplace for the origination, funding, sale, and trading of tokenized assets, today reported select unaudited preliminary operating data for the month and quarter ended September 30, 2026 that was at the high end of the Company’s previously issued guidance range of $4.8B – $5.2B.

Consumer Loan Marketplace Volume as presented in this release for September and Q3 2026 excludes volume originated on the Kiavi platform following the September 1, 2026 closing (“Merger”). The Company’s previously issued Q3 2026 guidance did not include the contribution of Kiavi. Kiavi loan volumes for the approximate one-month period post Merger will be included with Figure’s Q3 2026 financial results, to be released in November.

Dollars in Millions	September 2026		August 2026		M/M Change		September 2025		Y/Y Change
Consumer Loan Marketplace Volume1	$	1,783	$	1,640	9	%	$	876	104	%
$YLDS In Circulation2	$	504	$	446	13	%	$	21	n.m.
Democratized Prime3
Matched Offers Balance	$	588	$	583	1	%	$	22	n.m.
Borrower Demand	$	600	$	590	2	%	$	27	n.m.
Available Lender Supply	$	825	$	829	-1	%	$	26	n.m.

Dollars in Millions	Q3 2026		Q2 2026		Q/Q Change		Q3 2025		Y/Y Change
Consumer Loan Marketplace Volume1	$	5,119	$	4,259	20	%	$	2,469	107	%
$YLDS In Circulation2	$	504	$	556	-9	%	$	21	n.m.
Democratized Prime3
Matched Offers Balance	$	588	$	392	50	%	$	22	n.m.
Borrower Demand	$	600	$	414	45	%	$	27	n.m.
Available Lender Supply	$	825	$	522	58	%	$	26	n.m.

¹ Excludes volume originated on the Kiavi platform following the September 1, 2026 closing
² $YLDS launched in February 2025
³ Democratized Prime launched in June 2025

About Certain Operating Metrics

In order to better help understand our financial performance, we use several operating metrics, some of which are discussed below, to evaluate our business and results, measure performance, identify trends, formulate plans, and make strategic decisions. Our determination and presentation of these metrics may differ from that of other companies. The presentation of these metrics is meant to be considered in addition to, not as a substitute for or in isolation from, our financial measures prepared in accordance with GAAP.

Consumer Loan Marketplace Volume: We define Consumer Loan Marketplace Volume as the total U.S. dollar equivalent value of originations of HELOCs, DSCRs, and personal loans on our LOS, as well as the volume of third-party loans traded on Figure Connect. We believe this measure is an indication of our scale and represents the potential revenue opportunity from the technology used for consumer credit loan originations. This measure does not include the contribution from Figure’s recently closed transaction with Kiavi. Prior-period volumes will be recast following our next quarterly earnings release.

$YLDS in Circulation: We define $YLDS in Circulation as the total U.S. dollar equivalent value of unsecured face-amount certificates solely backed by the assets of Figure Certificate Company (FCC), which is the issuer of the certificates. This is reported as an end of period outstanding balance.

Matched Offers: We define Matched Offers as the U.S. dollar equivalent value of offers matched between borrowers and lenders on the Democratized Prime platform. This is reported as an end of period outstanding balance.

Borrower Demand: We define Borrower Demand as the U.S. dollar equivalent value that borrowers seek to borrow from the lending pool on the Democratized Prime platform. This is reported as an end of period outstanding balance.

Available Lender Supply: We define Lender Supply as the U.S. dollar equivalent value that lenders have made available in the lending pool on the Democratized Prime platform. This is reported as an end of period outstanding balance.

Financial Disclosure Advisory

The information in this release is unaudited and the information for the months in the most recent fiscal quarter is preliminary, based on Figure’s estimates, and subject to completion of financial closing procedures. Final results for the most recent fiscal quarter, as reported in Figure’s quarterly and annual filings with the U.S. Securities and Exchange Commission (“SEC”), might vary from the information in this release. Figure may at times make revisions to prior estimates to ensure consistency across comparable periods.

Forward Looking Statements Disclaimer

This press release contains forward-looking statements intended to be covered by the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release, including without limitation statements regarding our future financial performance, including our expectations regarding our operating data, guidance, the expected reconciliation of Kiavi’s contribution, and the recasting of prior-period volumes, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms, and similar expressions. Forward-looking statements are predictions based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These statements speak only as of the date of this press release.

Important factors that could cause actual results to differ materially include, among others: the ability of the Company to successfully integrate the business and operations of Kiavi; the ability to realize the anticipated benefits and synergies of the Merger; potential adverse effects on the Company’s business, financial condition and results of operations resulting from the Merger;  regulatory matters, including compliance with applicable laws and regulations; our history of losses and the risk that we may not maintain profitability; our reliance on HELOCs and exposure to fluctuations in the HELOC market and housing values; our ability to attract and retain borrowers, partners, and loan purchasers and to drive adoption of Figure-branded and Partner-branded channels including Figure Connect; loan performance and default rates and the effect of credit performance on access to and pricing of warehouse facilities, whole-loan sales, and securitizations; changes in interest rates and U.S. monetary policy that impact originations, funding costs, and investor demand; legal and regulatory risks affecting lending and mortgage-related activities and the evolving framework for digital assets, including potential changes in the characterization or regulation of certain digital assets and related products; dependence on key third-party providers including cloud, custodial, valuation, and data vendors and risks from outages or service disruptions; technology failures, cybersecurity incidents, or other operational disruptions; protection and enforcement of intellectual property; compliance with licensing, consumer protection, privacy, data security, and sanctions/AML laws, and shifting enforcement priorities at the federal and state levels; our ability to remediate previously identified material weaknesses and meet our public company reporting and internal control obligations; competition; macroeconomic and geopolitical conditions; our dual-class structure and concentrated voting control and related impacts on corporate governance; equity market volatility affecting our Class A common stock; and the other risks described in “Risk Factors” in our Annual Report on Form 10-K for the period ended December 31, 2025, filed with the SEC on March 16, 2026, our Quarterly Report on Form 10-Q for the three months ended June 30, 2026, filed with the SEC on August 14, 2026, and in our other filings with the SEC.

About Figure Technology Solutions, Inc

Figure is a blockchain-native capital marketplace that seamlessly connects origination, funding, and secondary market activity. More than 489 partners use its loan origination system and capital marketplace. Collectively, Figure and its partners have originated approximately $30 billion of home equity to date, among other products, making Figure’s ecosystem the largest non-bank provider of HELOCs. The fastest growing components are Figure Connect, its consumer credit marketplace, and Democratized Prime, Figure’s on-chain lend-borrow marketplace. Figure’s ecosystem also includes DART (Digital Asset Registry Technology) for asset custody and lien perfection, and $YLDS, an SEC-registered yield-bearing stablecoin that operates as a tokenized money market fund.

Figure is the market leader in real world asset (RWA) tokenization. The company has received AAA ratings from S&P and Moody’s on multiple loan securitizations, the first of its kind for blockchain finance. For more information, visit https://figure.com or follow Figure on LinkedIn.

News & Information Disclosure

Investors should note we may use our website (https://www.figure.com/), our investor relations website (https://investors.figure.com/), our operating metrics website (https://figure.com/investors/metrics) and the social media accounts of Figure, Figure Markets and/or Mike Cagney, our Co-Founder and Executive Chairman, as a means of disclosing information and for complying with our disclosure obligations under Regulation FD.  These include X (@figure, @mcagney, @figuremarkets), LinkedIn (https://www.linkedin.com/company/figuretechnologies/, https://www.linkedin.com/in/mikecagney/), Instagram (@figuretechnologies), Facebook (https://www.facebook.com/Figure/), and YouTube (@figuretechnologies).  The information we post through these channels may be deemed material. Investors should monitor these channels in addition to reviewing our press releases, SEC filings, and public conference calls.

Investor Contact: investors@figure.com